- Home
- SVRE vs CVKD Comparison
SVRE vs CVKD Comparison
Compare SVRE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- CVKD
- Stock Information
- Founded
- SVRE 2014
- CVKD 2022
- Country
- SVRE Israel
- CVKD United States
- Employees
- SVRE N/A
- CVKD N/A
- Industry
- SVRE
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- SVRE
- CVKD Health Care
- Exchange
- SVRE Nasdaq
- CVKD Nasdaq
- Market Cap
- SVRE 6.6M
- CVKD 6.9M
- IPO Year
- SVRE 2022
- CVKD 2023
- Fundamental
- Price
- SVRE $0.16
- CVKD $10.87
- Analyst Decision
- SVRE
- CVKD Strong Buy
- Analyst Count
- SVRE 0
- CVKD 2
- Target Price
- SVRE N/A
- CVKD $52.50
- AVG Volume (30 Days)
- SVRE 2.5M
- CVKD 48.9K
- Earning Date
- SVRE 08-27-2024
- CVKD 11-08-2024
- Dividend Yield
- SVRE N/A
- CVKD N/A
- EPS Growth
- SVRE N/A
- CVKD N/A
- EPS
- SVRE N/A
- CVKD N/A
- Revenue
- SVRE $458,952.00
- CVKD N/A
- Revenue This Year
- SVRE $219.30
- CVKD N/A
- Revenue Next Year
- SVRE $148.59
- CVKD N/A
- P/E Ratio
- SVRE N/A
- CVKD N/A
- Revenue Growth
- SVRE N/A
- CVKD N/A
- 52 Week Low
- SVRE $0.16
- CVKD $5.40
- 52 Week High
- SVRE $1.50
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- SVRE 29.81
- CVKD 68.57
- Support Level
- SVRE $0.18
- CVKD $6.89
- Resistance Level
- SVRE $0.18
- CVKD $11.99
- Average True Range (ATR)
- SVRE 0.02
- CVKD 0.83
- MACD
- SVRE -0.00
- CVKD 0.29
- Stochastic Oscillator
- SVRE 5.45
- CVKD 67.25
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.